HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
SRI 63-675
structure given in first source; PAF antagonist
Also Known As:
SDZ 63-675; SDZ-63-675; SRI 63675; SRI-63-675; dimethyltetrahydrofuran methoxyphosphinyloxyethylquinolinium; DL-erythro-Hexitol, 2,5-anhydro-3,4-dideoxy-2,5-di-C-methyl-, octadecylcarbamate 2-quinolinioethyl hydrogen phosphate
Networked:
12
relevant articles (
0
outcomes,
0
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Quinolines: 146
SRI 63-675: 12
Related Diseases
1.
Endotoxemia
05/01/1991 - "
Effect of SRI 63-675 on hemodynamics and blood PAF levels during porcine endotoxemia.
"
05/01/1991 - "
We evaluated the effect of SRI 63-675, a specific platelet-activating factor (PAF) receptor antagonist, on hemodynamics and PAF biosynthesis during 4 h of porcine endotoxemia.
"
06/01/1990 - "
These phase I effects were attenuated or blocked by SRI 63-675 (10 mg/kg before endotoxin + 3 mg.kg-1.h-1 during endotoxemia).
"
03/01/1989 - "
Because increased levels of platelet activating factor (PAF) have been observed in experimental models of endotoxemia, we pretreated rats with PAF receptor antagonist BN 52021 or SRI 63-675 before administering endotoxin.
"
08/01/1990 - "
SRI 63-675 (10 mg/kg before endotoxin + 3 mg/kg/hour during endotoxemia) blocked or attenuated endotoxin-induced pulmonary hypertension, bronchoconstriction, hypoxemia, thrombocytopenia, increased permeability of the alveolar-capillary membrane, and the increases in plasma (at 3 and 4 hours) and bronchoalveolar lavage fluid concentrations of 5-, 12-, and 15-HETE.
"
2.
Hypotension (Low Blood Pressure)
10/15/1991 - "
Hypotension was prevented or reverted by the platelet activating factor (PAF) antagonist SRI 63-675.
"
05/01/1989 - "
In normal Wistar rats, SDZ 63-675 (1.2 mg/kg) inhibited hypotension and hemoconcentration induced by PAF-acether (0.2-0.8 micrograms/kg.min).
"
02/01/1993 - "
In addition, SDZ 63-675 and WEB 2170 prevented early transient bradycardia and hypotension and reduced the infarct size, judged by staining with tetrazolium at 2 and 24 hours after reperfusion, and by histological examination at 24 hours.
"
03/01/1993 - "
Infusion of the thrombolytic agents streptokinase (SK, 666 units/kg per minute for 60 minutes) and tissue-type plasminogen activator (t-PA, 10 micrograms/kg per minute for 15 minutes) in rabbits induced a significant hypotension and decrease in platelet count that were completely prevented by treatment with platelet-activating factor (PAF) receptor antagonists SDZ 63-675 and WEB 2170.
"
3.
Pulmonary Hypertension
05/01/1991 - "
The endotoxin-induced pulmonary hypertension, decreased cardiac index, and increases in pulmonary vascular resistance and alveolar-arterial O2 gradient were attenuated by SRI 63-675.
"
02/01/1991 - "
Bolus injection of SRI 63-675 at the time of Ps infusion blocked the early pulmonary hypertension, attenuated the early and late fall in PaO2, ameliorated the increase in EVLW, and prevented the late (150-180 min) increase in albumin flux.
"
08/01/1990 - "
SRI 63-675 (10 mg/kg before endotoxin + 3 mg/kg/hour during endotoxemia) blocked or attenuated endotoxin-induced pulmonary hypertension, bronchoconstriction, hypoxemia, thrombocytopenia, increased permeability of the alveolar-capillary membrane, and the increases in plasma (at 3 and 4 hours) and bronchoalveolar lavage fluid concentrations of 5-, 12-, and 15-HETE.
"
4.
Lung Injury
02/01/1991 - "
We investigated the role of platelet-activating factor (PAF) in acute septic lung injury by examining the effects of the selective PAF antagonist SRI 63-675 and by measuring PAF in lung tissue in the porcine model.
"
5.
Thrombocytopenia (Thrombopenia)
08/01/1990 - "
SRI 63-675 (10 mg/kg before endotoxin + 3 mg/kg/hour during endotoxemia) blocked or attenuated endotoxin-induced pulmonary hypertension, bronchoconstriction, hypoxemia, thrombocytopenia, increased permeability of the alveolar-capillary membrane, and the increases in plasma (at 3 and 4 hours) and bronchoalveolar lavage fluid concentrations of 5-, 12-, and 15-HETE.
"
Related Drugs and Biologics
1.
Platelet Activating Factor
2.
Endotoxins
3.
bepafant
4.
platelet activating factor receptor
5.
Streptokinase
6.
Pyrilamine (Mepyramine)
7.
Tissue Plasminogen Activator (Alteplase)
8.
Metiamide
9.
Methysergide (Sansert)
10.
Indomethacin (Indometacin)